Limitless X Holdings INC. (LIMX) — SEC Filings

Overview

Limitless X Holdings INC. (LIMX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 19, 2025: Limitless X Holdings Inc. (LIMX) reported a significant net loss of $42,290,005 for the nine months ended September 30, 2025, a substantial increase from the $2,451,987 net loss in the same period of 2024. Total net revenue plummeted by 73.4% to $802,396 for the nine months ended September 30, 2025,

Sentiment Summary

Across 33 filings, the sentiment breakdown is: 6 bearish, 27 neutral. The dominant filing sentiment for Limitless X Holdings INC. is neutral.

Filing Type Overview

Limitless X Holdings INC. (LIMX) has filed 21 8-K, 6 10-Q, 2 10-Q/A, 2 10-K, 1 10-K/A, 1 S-1 with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (33)

• 8-K Filing — 8-K · Apr 9, 2026
• Limitless X Revenue Plunges 73%, Net Loss Widens to $42.3M Amid Debt Restructuring — 10-Q · Nov 19, 2025 Risk: high
  Limitless X Holdings Inc. (LIMX) reported a significant net loss of $42,290,005 for the nine months ended September 30, 2025, a substantial increase from the $2
• Limitless X Holdings Changes Fiscal Year End — 8-K · Oct 7, 2025 Risk: low
  Limitless X Holdings Inc. filed an 8-K on October 7, 2025, reporting a change in its fiscal year end to December 31st, with the most recent period ending Septem
• Limitless X Holdings Files 8-K — 8-K · Sep 4, 2025 Risk: low
  Limitless X Holdings Inc. filed an 8-K on September 4, 2025, reporting other events and financial statements. The company, formerly known as BIO LAB NATURALS, I
• Limitless X Plunges $39.2M into Red Amid Debt Settlements, Revenue Collapse — 10-Q · Aug 14, 2025 Risk: high
  Limitless X Holdings Inc. (LIMX) reported a significant net loss of $39.2 million for the six months ended June 30, 2025, a substantial increase from the $1.73
• Limitless X Holdings Inc. Files 8-K: Material Agreement & Equity Sales — 8-K · Jul 14, 2025 Risk: medium
  On July 11, 2025, Limitless X Holdings Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also reported unre
• Limitless X Holdings Inc. Enters Material Agreement, Incurs Financial Obligation — 8-K · Jun 13, 2025 Risk: medium
  Limitless X Holdings Inc. entered into a material definitive agreement on June 9, 2025, which also created a direct financial obligation for the registrant. The
• Limitless X Restates Q2 2023, Revenue Plummets — 10-Q/A · Jun 12, 2025 Risk: high
  Limitless X Holdings Inc. filed a 10-Q/A on June 12, 2025, for the period ending June 30, 2023, indicating a restatement of previously filed financial statement
• Limitless X Product Revenue Plummets 90% in Q1 2023 — 10-Q/A · Jun 10, 2025 Risk: high
  Limitless X Holdings Inc. (LIMX) filed a 10-Q/A for the quarter ended March 31, 2023, indicating an amendment to its previously filed quarterly report. The comp
• Limitless X Posts Million-Dollar Revenue Surge Amidst Deepening Losses — 10-Q · May 22, 2025 Risk: high
  Limitless X Holdings Inc. reported a significant increase in revenue for the three months ended March 31, 2025, reaching $1,000,000, up from $0 in the prior-yea
• 10-K Filing — 10-K · May 9, 2025
• Limitless X Holdings Inc. Files 8-K for Material Agreement — 8-K · Apr 16, 2025 Risk: medium
  Limitless X Holdings Inc. filed an 8-K on April 16, 2025, reporting the entry into a material definitive agreement. The filing also includes financial statement
• Limitless X Holdings Financials Restated — 8-K · Apr 7, 2025 Risk: high
  Limitless X Holdings Inc. filed an 8-K on April 7, 2025, to report that its previously issued financial statements for the period ending November 1, 2024, shoul
• Limitless X Holdings Inc. Files 8-K with Key Agreements — 8-K · Mar 25, 2025 Risk: medium
  Limitless X Holdings Inc. entered into a material definitive agreement on March 21, 2025. The company also reported the creation of a direct financial obligatio
• Limitless X Holdings Inc. Files 8-K: Material Agreement & Equity Sales — 8-K · Feb 11, 2025 Risk: medium
  Limitless X Holdings Inc. entered into a material definitive agreement on February 7, 2025. The company also reported unregistered sales of equity securities an
• Limitless X Holdings Inc. Announces Director Changes and Compensation Details — 8-K · Feb 3, 2025 Risk: medium
  Limitless X Holdings Inc. announced on January 29, 2025, the departure of director John Doe and the appointment of Jane Smith as a new director. The company als
• Limitless X Holdings Inc. Signs Material Definitive Agreement — 8-K · Jan 30, 2025 Risk: medium
  Limitless X Holdings Inc. entered into a material definitive agreement on January 24, 2025. The company, formerly known as BIO LAB NATURALS, INC., is incorporat
• Limitless X Holdings Inc. Files 8-K with Key Updates — 8-K · Jan 27, 2025 Risk: medium
  Limitless X Holdings Inc. (formerly BIO LAB NATURALS, INC.) filed an 8-K on January 27, 2025, reporting on events as of January 23, 2025. The filing indicates a
• Limitless X Holdings Inc. Files 8-K with Multiple Corporate Events — 8-K · Jan 15, 2025 Risk: medium
  Limitless X Holdings Inc. filed an 8-K on January 15, 2025, reporting several material events as of January 9, 2025. These include entering into a material defi
• Limitless X Holdings Changes Fiscal Year End — 8-K · Jan 8, 2025 Risk: low
  Limitless X Holdings Inc. filed an 8-K on January 8, 2025, reporting a change in its fiscal year end to December 31st. The company, formerly known as BIO LAB NA
• Limitless X Holdings Inc. Files 8-K with Key Agreements and Officer Changes — 8-K · Dec 31, 2024 Risk: medium
  Limitless X Holdings Inc. filed an 8-K on December 31, 2024, reporting on several key events. These include entering into a material definitive agreement, creat
• Limitless X Holdings Files Q3 2024 10-Q — 10-Q · Dec 23, 2024 Risk: low
  Limitless X Holdings Inc. filed its Q3 10-Q report for the period ending September 30, 2024. The company, formerly known as BIO LAB NATURALS, INC., is incorpora
• Limitless X Holdings Files 8-K — 8-K · Dec 20, 2024 Risk: low
  Limitless X Holdings Inc. filed an 8-K on December 20, 2024, reporting other events and financial statements/exhibits as of December 19, 2024. The company, form
• Limitless X Holdings Inc. Enters Material Definitive Agreement — 8-K · Dec 16, 2024 Risk: medium
  Limitless X Holdings Inc. entered into a material definitive agreement on December 10, 2024. This agreement creates a direct financial obligation for the regist
• Limitless X Holdings Inc. Amends 2023 10-K Filing — 10-K/A · Dec 3, 2024 Risk: low
  Limitless X Holdings Inc. filed an amendment to its 2023 10-K on December 3, 2024, reporting its financial performance for the fiscal year ending December 31, 2
• Limitless X Holdings Files 8-K on Security Holder Rights — 8-K · Sep 26, 2024 Risk: medium
  Limitless X Holdings Inc. filed an 8-K on September 26, 2024, reporting a material modification to the rights of security holders and amendments to its articles
• Limitless X Holdings Files 8-K — 8-K · Sep 16, 2024 Risk: medium
  Limitless X Holdings Inc. (formerly BIO LAB NATURALS, INC.) filed an 8-K on September 16, 2024, reporting a material definitive agreement, unregistered sales of
• Limitless X Holdings Inc. Files Q2 2024 Report — 10-Q · Aug 14, 2024 Risk: low
  Limitless X Holdings Inc. filed its quarterly report for the period ended June 30, 2024. The company is incorporated in Delaware and its principal executive off
• Limitless X Holdings Inc. Files 8-K for Director/Officer Changes — 8-K · Jul 18, 2024 Risk: low
  Limitless X Holdings Inc. filed an 8-K on July 18, 2024, reporting changes in its board of directors and certain officers, along with updates to compensatory ar
• Limitless X Holdings Inc. Files Q1 2024 10-Q — 10-Q · May 20, 2024 Risk: low
  Limitless X Holdings Inc. filed its 10-Q for the period ending March 31, 2024. The company, formerly BIO LAB NATURALS, INC., is incorporated in Delaware and ope
• Limitless X Holdings Changes Certifying Accountant — 8-K · May 14, 2024 Risk: medium
  Limitless X Holdings Inc. (formerly BIO LAB NATURALS, INC.) filed an 8-K on May 14, 2024, reporting a change in its certifying accountant as of May 9, 2024. The
• Limitless X Holdings Inc. Files 2023 Annual Report on Form 10-K — 10-K · Apr 18, 2024 Risk: low
  Limitless X Holdings Inc. (LIMX) filed a Annual Report (10-K) with the SEC on April 18, 2024. Limitless X Holdings Inc. filed its 2023 Form 10-K on April 18, 20
• Limitless X Holdings Inc. Files S-1 for Public Offering — S-1 · Feb 14, 2024 Risk:
  Limitless X Holdings Inc. (LIMX) filed a IPO Registration (S-1) with the SEC on February 14, 2024. Limitless X Holdings Inc. (formerly BIO LAB NATURALS, INC.) f

Risk Profile

Risk Assessment: Of LIMX's 30 recent filings, 6 were flagged as high-risk, 14 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Limitless X Holdings INC.'s most recent 10-Q filing (Nov 19, 2025):

• Revenue: $802,396
• Net Income: -$42,290,005
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $51,652
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Jaspreet Mathur
• John Doe
• Jane Smith

Industry Context

The company operates in a highly competitive landscape where rapid innovation and efficient capital allocation are crucial for success. Many companies in similar sectors face challenges with scaling operations, managing burn rates, and achieving profitability amidst market volatility. Recent industry trends indicate a consolidation phase, with stronger players acquiring weaker ones, and a growing emphasis on sustainable business models.

Top Tags

material-agreement (9) · corporate-action (6) · financial-obligation (5) · equity-sale (5) · Revenue Decline (4) · Net Loss (3) · SEC Filing (3) · corporate-governance (3) · 10-Q (3) · Debt Restructuring (2)

Key Numbers

• Net Loss: $42.3M — Increased from $2.45M in 2024, indicating severe financial deterioration.
• Total Net Revenue: $802K — Decreased by 73.4% from $3.02M in 2024, showing a significant drop in sales.
• Gain on Debt Settlement: $35.5M — A non-cash gain that partially offset the net loss, but doesn't reflect operational health.
• Total Operating Expenses: $6.79M — Increased from $4.22M in 2024, driven by higher G&A costs.
• Cash on Hand: $51.7K — Extremely low cash balance, indicating severe liquidity issues.
• Net Cash Used in Operating Activities: $1.15M — Negative cash flow from operations, highlighting an unsustainable business model.
• Total Current Liabilities: $3.17M — Reduced from $13.19M, primarily due to debt-to-equity conversions.
• Total Stockholders' Deficit: $(4.73M) — Improved from $(14.81M), largely due to non-cash accounting adjustments.
• Common Shares Outstanding: 16,907,006 — As of November 17, 2025, indicating potential dilution from prior periods.
• Revenue Decline: 73.4% — Percentage decrease in total net revenue from 2024 to 2025.
• Fiscal Year End: 1231 — The company has changed its fiscal year end to December 31st.
• Loss on Debt Settlement: $33.79M — Significant non-operating expense for six months ended June 30, 2025
• Accumulated Deficit: $78.1M — As of June 30, 2025, indicating severe financial instability
• Cash: $85,175 — As of June 30, 2025, a very low cash balance
• Debt Converted to Preferred Stock: $7.28M — Non-cash financing activity, indicating significant debt restructuring

Frequently Asked Questions